Compare SVC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | ACRS |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.6M | 311.0M |
| IPO Year | 1995 | 2015 |
| Metric | SVC | ACRS |
|---|---|---|
| Price | $1.33 | $3.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.50 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 14.8M | 1.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | 26.95 | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,814,838,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.86 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $1.09 |
| 52 Week High | $3.08 | $4.89 |
| Indicator | SVC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 32.75 | 54.50 |
| Support Level | $1.13 | $3.16 |
| Resistance Level | $2.42 | $4.22 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 29.50 | 62.22 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its segments hotel investment unit, and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza, Hyatt Place, and others.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.